PURPOSE Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early
detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or …

Abstract Background: In a European cohort, it was previously reported that 35% of
oropharyngeal cancer (OPC) patients were human papillomavirus type-16 (HPV16) …

Background The lack of detectable precancerous lesions poses challenges to the early
detection of human papillomavirus-driven oropharyngeal cancer (HPV-OPC). Antibodies …

Background: The increasing incidence of oropharyngeal cancer in many developed
countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently …

Background Human papillomavirus type 16 (HPV16) E6 antibodies are a promising
biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is …

Background Human papillomavirus type 16 (HPV16)-E6 antibodies are detectable in
peripheral blood before diagnosis in the majority of HPV16-driven oropharyngeal squamous …

Purpose Human papillomavirus type 16 (HPV16) infection is causing an increasing number
of oropharyngeal cancers in the United States and Europe. The aim of our study was to …

Background Human papillomavirus (HPV)‐related oropharyngeal cancer screening is being
explored in research studies, but strategies to identify an appropriate population are not …

Importance The incidence of human papillomavirus (HPV)–positive oropharyngeal cancer
(OPC) is anticipated to rise over the next few decades until the effects of prophylactic …

BACKGROUND Human papillomavirus 16 (HPV16) E6 antibodies may be an early marker
of the diagnosis and recurrence of human papillomavirus–driven oropharyngeal cancer …